Investigational drug · Phase 3
MI078
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postpartum Depression (PPD), Postpartum Depression.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "MI078"
First trial start
2024
Sep 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MI078", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postpartum Depression (PPD)
- Postpartum Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Postpartum depression · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "MI078" as an intervention, largest first.
- A Study of MI078 for Postpartum DepressionPivotal-lookingRecruiting
Nanjing Minova Pharmaceutical Co., Ltd.Industry
NCT07721961 · 200 participants (planned) · Start Jul 10, 2026 · Primary completion Dec 2027
Drug: MI078 capsule; Placebo of MI078 capsules · For: Postpartum Depression (PPD)
Sites: Hefei, China; Chongqing, China; Xiamen, China · 36 sites in all
Nanjing Minova Pharmaceutical Co., Ltd.Industry
NCT06982651 · 98 participants · Start Sep 9, 2023 · Primary completion Mar 18, 2024
Drug: MI078; Placebo · For: Postpartum Depression
Sites: Changsha, China
Nanjing Minova Pharmaceutical Co., Ltd.Industry
NCT06963580 · 72 participants · Start Sep 9, 2024 · Primary completion Aug 7, 2025
Drug: MI078 capsule dose 1; MI078 capsule dose 2 and 1 more · For: Postpartum Depression
Sites: Wuhu, China; Beijing, China; Xiamen, China · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.